Xencor begins Phase II trials of XmAb5871 for IgG4-related disease and SLE

US-based Xencor has started a Phase II trial of its drug candidate XmAb5871 in patients with IgG4-related disease (IgG4-RD), as well as patients with systemic lupus erythematosus (SLE).

Source: Drug Development Technology - March 9, 2016 Category: Pharmaceuticals Source Type: news